HRP20181038T1 - Terapija za neurološke poremećaje zasnovana na baklofenu i akamprosatu - Google Patents
Terapija za neurološke poremećaje zasnovana na baklofenu i akamprosatu Download PDFInfo
- Publication number
- HRP20181038T1 HRP20181038T1 HRP20181038TT HRP20181038T HRP20181038T1 HR P20181038 T1 HRP20181038 T1 HR P20181038T1 HR P20181038T T HRP20181038T T HR P20181038TT HR P20181038 T HRP20181038 T HR P20181038T HR P20181038 T1 HRP20181038 T1 HR P20181038T1
- Authority
- HR
- Croatia
- Prior art keywords
- acamprosate
- baclofen
- composition according
- pharmaceutically acceptable
- composition
- Prior art date
Links
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title claims 19
- 229960004047 acamprosate Drugs 0.000 title claims 19
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 title claims 18
- 229960000794 baclofen Drugs 0.000 title claims 18
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 2
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 claims 2
- 229960003974 diethylcarbamazine Drugs 0.000 claims 2
- 229960003998 ifenprodil Drugs 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 claims 2
- 229960000692 levosimendan Drugs 0.000 claims 2
- 229960003404 mexiletine Drugs 0.000 claims 2
- 229960000654 sulfafurazole Drugs 0.000 claims 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 2
- 229960002722 terbinafine Drugs 0.000 claims 2
- 229960005461 torasemide Drugs 0.000 claims 2
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 claims 1
- QPQOSNABCLSMQQ-UHFFFAOYSA-N 3-acetamidopropane-1-sulfonic acid 4-amino-3-(4-chlorophenyl)butanoic acid Chemical compound CC(=O)NCCCS(O)(=O)=O.OC(=O)CC(CN)C1=CC=C(Cl)C=C1 QPQOSNABCLSMQQ-UHFFFAOYSA-N 0.000 claims 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229920000439 Sulodexide Polymers 0.000 claims 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 229960000530 carbenoxolone Drugs 0.000 claims 1
- RFXQCUDAHXPYOF-UHFFFAOYSA-N diphyllin Natural products COc1cc2c(c3ccc4OCOc4c3)c5C(=O)OCc5c(O)c2cc1O RFXQCUDAHXPYOF-UHFFFAOYSA-N 0.000 claims 1
- 229960002819 diprophylline Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 1
- 229960001208 eplerenone Drugs 0.000 claims 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims 1
- 229960001690 etomidate Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960000901 mepacrine Drugs 0.000 claims 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- 229960003243 phenformin Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960003491 sulodexide Drugs 0.000 claims 1
- 229960002178 thiamazole Drugs 0.000 claims 1
- 229960001177 trimetazidine Drugs 0.000 claims 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 1
- 229960002911 zonisamide Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Sastav koji sadrži baklofen ili njegovu farmaceutski prihvatljivu sol, i akamprosat ili njegovu farmaceutski prihvatljivu sol.
2. Sastav prema patentnom zahtjevu 1, koji nadalje sadrži barem jedan spoj izabran od sulfisoksazola, metimazola, prilokaina, difilina, kvinakrina, karbenoksolona, aminokaproične kiseline, kabergolina, dietilkarbamazina, kinakalceta, kinarizina, eplererona, fenoldopama, leflunomida, levosimendana, sulodeksida, terbinafina, zonisamida, etomidata, fenformina, trimetazidina, meksiletina, ifenprodila, moksifloksacina, bromokriptina ili torasemida, ili njihove farmaceutski prihvatljive soli.
3. Sastav prema patentnom zahtjevu 1 ili 2, gdje spomenuti sastav sadrži barem jednu od sljedećih kombinacija spojeva:
baklofen i akamprosat,
baklofen i akamprosat i dietilkarbamazin,
baklofen i akamprosat i kinakalcet,
baklofen i akamprosat i sulfisoksazol,
baklofen i akamprosat i torasemid,
baklofen i akamprosat i ifenprodil,
baklofen i akamprosat i meksiletin,
baklofen i akamprosat i eplerenon,
baklofen i akamprosat i levosimendan,
baklofen i akamprosat i terbinafin, ili
baklofen i akamprosat i leflunomid,
ili njihove farmaceutski prihvatljive soli.
4. Sastav prema patentnom zahtjevu 1, koji sadrži barem jednu od sljedećih kombinacija spojeva:
baklofen, akamprosat i rivastigmin,
baklofen, akamprosat i memantin, ili
baklofen, akamprosat i i gabapentin,
ili njihove farmaceutski prihvatljive soli.
5. Sastav prema patentnom zahtjevu 1, koji sadrži baklofen i akamprosat ili njihove farmaceutski prihvatljive soli, kao jedine aktivne tvari.
6. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, koji nadalje sadrži farmaceutski prihvatljivi nosač ili ekscipijens.
7. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, gdje su spojevi formulirani za kombiniranu ili odvojenu primjenu.
8. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, gdje je spomenuti sastav prilagođen za oralnu primjenu.
9. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, gdje je omjer akamprosat/baklofen (W/W) sadržan između 0.05 i 1000.
10. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, gdje je spomenuti sastav formuliran u doznom obliku s jednom ili više jedinica, prikladno za dnevnu uporabu.
11. Sastav prema patentnom zahtjevu 10, gdje je ukupna doza baklofena prikladna za dnevnu uporabu manje od 100 mg.
12. Sastav prema patentnom zahtjevu 10 ili 11, gdje je ukupna doza akamprosata prikladna za dnevnu uporabu manje od 1000 mg.
13. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, koji sadrži kalcijevu sol akamprosata.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305217 | 2011-03-01 | ||
| US201161468658P | 2011-03-29 | 2011-03-29 | |
| US201161493606P | 2011-06-06 | 2011-06-06 | |
| EP11305687 | 2011-06-06 | ||
| EP13196468.6A EP2796132B1 (en) | 2011-03-01 | 2012-03-01 | Baclofen and acamprosate based therapy of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20181038T1 true HRP20181038T1 (hr) | 2018-09-07 |
Family
ID=63363405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181038TT HRP20181038T1 (hr) | 2011-03-01 | 2018-07-05 | Terapija za neurološke poremećaje zasnovana na baklofenu i akamprosatu |
| HRP20181945TT HRP20181945T1 (hr) | 2011-03-01 | 2018-11-21 | Liječenje neuroloških poremećaja na bazi baklofena i akamprozata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181945TT HRP20181945T1 (hr) | 2011-03-01 | 2018-11-21 | Liječenje neuroloških poremećaja na bazi baklofena i akamprozata |
Country Status (4)
| Country | Link |
|---|---|
| HR (2) | HRP20181038T1 (hr) |
| HU (1) | HUE042034T2 (hr) |
| IL (1) | IL256992B (hr) |
| PT (2) | PT2727588T (hr) |
-
2012
- 2012-03-01 PT PT13196461T patent/PT2727588T/pt unknown
- 2012-03-01 PT PT131964686T patent/PT2796132T/pt unknown
- 2012-03-01 HU HUE13196461A patent/HUE042034T2/hu unknown
-
2018
- 2018-01-18 IL IL256992A patent/IL256992B/en active IP Right Grant
- 2018-07-05 HR HRP20181038TT patent/HRP20181038T1/hr unknown
- 2018-11-21 HR HRP20181945TT patent/HRP20181945T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2727588T (pt) | 2018-12-05 |
| IL256992B (en) | 2020-09-30 |
| PT2796132T (pt) | 2018-07-13 |
| IL256992A (en) | 2018-03-29 |
| HUE042034T2 (hu) | 2019-06-28 |
| HRP20181945T1 (hr) | 2019-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140131T1 (hr) | Lijeäśenje neuroloških poremeä†aja na bazi baklofena i akamprozata | |
| MX2022013590A (es) | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. | |
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| IN2015DN01662A (hr) | ||
| HRP20150369T1 (hr) | Novi farmaceutski pripravak otporan na zlouporabu za tretiranje zavisnosti o opioidima | |
| JP2013525444A5 (hr) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2014516380A5 (hr) | ||
| IL220066A0 (en) | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them | |
| BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
| JP2013516493A5 (hr) | ||
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| ES2609820T3 (es) | Inhaladores de polvo seco que comprenden un vehículo distinto de lactosa | |
| MX2013014849A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia. | |
| HRP20181038T1 (hr) | Terapija za neurološke poremećaje zasnovana na baklofenu i akamprosatu | |
| WO2013086243A3 (en) | Phospholipid compositions enriched for palmitoleic, myristoleic or lauroleic acid, their preparation and their use in treating metabolic and cardiovascular disease | |
| WO2010136036A3 (en) | Calcium-sensing receptor-active compounds | |
| PH12014502836A1 (en) | Medicament form for release of active ingredients | |
| JP2014518280A5 (hr) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| UA108277C2 (ru) | Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения | |
| HK1178881A1 (en) | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |